Focused On-demand Library for Probable RNA polymerase II nuclear localization protein SLC7A6OS

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96CW6

UPID:

S7A6O_HUMAN

Alternative names:

ADAMS proteinase-related protein; Solute carrier family 7 member 6 opposite strand transcript

Alternative UPACC:

Q96CW6; Q8TCZ3; Q9H8R8

Background:

The Probable RNA polymerase II nuclear localization protein SLC7A6OS, also known as ADAMS proteinase-related protein and Solute carrier family 7 member 6 opposite strand transcript, plays a pivotal role in directing RNA polymerase II nuclear import. This process is crucial for the transcription of DNA into RNA, a fundamental step in gene expression and cellular function.

Therapeutic significance:

SLC7A6OS is linked to Epilepsy, progressive myoclonic 12 (EPM12), a disorder characterized by seizures, neurodegeneration, and neurocognitive impairment. Understanding the role of SLC7A6OS could open doors to potential therapeutic strategies for this debilitating condition.